

Bioluminescent Assays For Measuring Steatosis and Insulin Action

Michael P. Valley, Natasha Karassina, and Jolanta Vidugiriene


Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711

Poster #3035




1. Bioluminescent Metabolite Detection Assays

Nonalcoholic fatty liver disease (NAFLD), and its more serious form nonalcoholic steatohepatitis (NASH), are conditions in which lipids accumulate in the liver. To study these diseases, it is not only important to find good cellular models of steatosis, but it is also important to develop better assays to measure changes in lipid accumulation. Staining is routinely used to monitor lipid levels, but this is often nonspecific, somewhat laborious, and not quantitative. There are quantitative assays available, but most require an organic extraction, which is also undesirable.




We have developed a core bioluminescent technology that couples specific metabolite dehydrogenases to the production of NAD(P)H and the generation of light. These assays rely on detergents for lysis and extraction of lipids, hence, by utilizing specific dehydrogenases, lipases, and esterases, we can quantify triglyceride, cholesterol, and cholesterol esters without the requirement for an organic solvent.

2. Metabolite Detection Technology: light \approx [metabolite]





3. General Protocol and Standard Curves




4. Organic vs Detergent Extraction of Lipids


Lipids were extracted from mature adipocytes by organic solvent or detergent lysis solutions and assayed with the bioluminescent assays.



5. Lipid Accumulation During Adipocyte Differentiation




6. HepG2 as a model for NAFLD




20,000 HepG2 cells per well were incubated overnight in the absence or presence of 0.3 mM BSA-bound linoleic and oleic acids to induce normal or steatotic conditions. Cells were washed with PBS and assayed with the triglyceride detection assay.

7. Cholesterol and Cholesteryl Esters in Lipoproteins

Human High Density Lipoprotein (HDL, 10 mg/ml) and Human Low Density Lipoprotein (LDL, 5 mg/ml) were purchased from Kalen Biomedical, LLC. Because of the high amounts of lipid and our assay's \sim 80 uM limit of linearity, samples were diluted 4000-fold prior to assay. Samples in the lower graph were pulled from the supernatant after treatment with an LDL Precipitation Buffer (Sigma).




8. Insulin Action: Gluconeogenesis and Lipolysis



Microtissues (InSphero) formed from 2000 iCell[®] Hepatocytes 2.0 (CD1) were washed and incubated with 10 mM lactate, 2 uM forskolin, and a titration of insulin for 6 hours. An aliquot of media was then assayed with the glucose detection assay.

3T3-L1 MBX adipocytes were washed and treated for 90 minutes with different combinations of isoproterenol (25 nM) and insulin (150 nM). An aliquot of media was then assayed with the glycerol detection assay.



9. Conclusions

A variety of metabolites can be measured in a variety of sample types with these bioluminescent detections assays.

Metabolites

NAD(P)/NAD(P)H
glucose
lactate
glutamine
glutamate
2DG6P
glycerol/triglyceride
cholesterol/cholesteryl esters
branched-chain amino acids

Sample Types

cancer cells
primary cells
stem cells
immune cells
3D microtissues
bacteria
yeast